(210) | Number of the EPO application | 16735945 |
(220) | Filing date of the EPO application | 2016.07.01 |
(80) | EPO patent specification publication (B) | EPB nr. 17/2020, 2020.04.22 |
(110) | EPO patent number | 3317281 |
(11) | Number of the document | MD 3317281 T2 |
(21) | Number of the application | e 2018 0479 |
(71) | Name(s) of applicant(s), code of the country | Acerta Pharma B.V., NL; |
(72) | Name(s) of inventor(s), code of the country | BLATTER Fritz, CH; INGALLINERA Tim, US; BARF Tjeerd, NL; ARET Edwin, NL; KREJSA Cecile, US; EVARTS Jerry, US; |
(73) | Name(s) of owner(s), code of the country | ACERTA Pharma B.V., NL; |
(54) | Title of the invention | Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide |
(13) | Kind-of-document code | T2 |
(51) | International Patent Classification | C07D 487/04 (2006.01.01); A61K 31/4985 (2006.01.01); A61P 35/00 (2006.01.01) |
(19) | Country | NL |
(41) | Date of publication of the application | 2018.06.30 |
(49) | Date of publication of the translation of the validated European patent specification | 2020.07.31 |
(30) | Priority | 201562188468 P, 2015.07.02, US; 201562271708 P, 2015.12.28, US |
(74) | Patent attorney | (Procedură) CORCODEL Angela, Bd. Ştefan cel Mare nr. 134, Chişinău, Republica Moldova |
(86) | International application | PCT/IB2016/053988, 2016.07.01 |
(87) | International publication | WO 2017/002095, 2017.01.05 |